Hangzhou Jiuyuan Genetic Biopharmaceutical (2566) Stock Overview
A biopharmaceutical company, engages in the research, development, production, and sale of biopharmaceutical products and medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2566 from our risk checks.
2566 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.52 |
| 52 Week High | HK$16.29 |
| 52 Week Low | HK$5.18 |
| Beta | 0 |
| 1 Month Change | -23.42% |
| 3 Month Change | -50.49% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.70% |
Recent News & Updates
Recent updates
Hangzhou Jiuyuan Genetic Biopharmaceutical (HKG:2566) Seems To Use Debt Quite Sensibly
Sep 24
Subdued Growth No Barrier To Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566) With Shares Advancing 26%
Jul 28Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.'s (HKG:2566) Popularity With Investors Is Under Threat From Overpricing
Jun 10Shareholder Returns
| 2566 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 0.3% | 7.7% | 1.8% |
| 1Y | n/a | 124.8% | 39.6% |
Return vs Industry: Insufficient data to determine how 2566 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2566 performed against the Hong Kong Market.
Price Volatility
| 2566 volatility | |
|---|---|
| 2566 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 2566 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2566's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1,629 | Hang Fu | www.china-gene.com |
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of biopharmaceutical products and medical devices. The company offers Guyoudao, a recombinant human bone morphogenetic protein-2 bone repair product; Jilifen, a human granulocyte colony-stimulating factor injection for neutropenia; Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by radiation therapy, chemotherapy, or postoperative conditions. It also provides Jifuwei, a fulvestrant injection for advanced breast cancer; Jitansu, a fosaprepitant dimeglumine injection for chemotherapy-induced nausea and vomiting; Jixinfen, a polyethylene glycol-modified human granulocyte colony-stimulating factor injection for neutropenia; Jipailin, a low molecular weight heparin sodium injection for venous thromboembolic diseases; and Yinuojia, an enoxaparin sodium injection for venous thromboembolic diseases.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Fundamentals Summary
| 2566 fundamental statistics | |
|---|---|
| Market cap | HK$1.85b |
| Earnings (TTM) | HK$135.14m |
| Revenue (TTM) | HK$1.43b |
Is 2566 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2566 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.31b |
| Cost of Revenue | CN¥239.26m |
| Gross Profit | CN¥1.07b |
| Other Expenses | CN¥942.91m |
| Earnings | CN¥123.43m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 81.67% |
| Net Profit Margin | 9.45% |
| Debt/Equity Ratio | 8.6% |
How did 2566 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/15 11:46 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.